Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy and future perspectives
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, cilt.46, sa.12, ss.1519-1525, 2023 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 46 Sayı: 12
- Basım Tarihi: 2023
- Doi Numarası: 10.1111/pace.14876
- Dergi Adı: PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, SportDiscus
- Sayfa Sayıları: ss.1519-1525
- Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır
Özet
Background: The hypertrophic cardiomyopathy (HCM) risk- sudden cardiac death (SCD) model provides a convenient tool for determining the risk of SCD in patients with HCM even though some patients with low-risk scores still remain at risk of SCD. Hence, the aim of our study was to assess the performance of HCM Risk-SCD in a large series of consecutive patients with HCM who had been followed up in a tertiary center.Methods: The study population consisted of 389 consecutive HCM patients who had been followed up between 2004 and 2021. Demographic and clinical characteristics, estimated 5-year risk using the HCM Risk-SCD model, were compiled, and survival data were collected during follow-up. Patients were divided into 2 groups according to their long-term survival, and HCM risk-SCD scores of these two groups were compared.Results: The long-term mortality was observed in 47 patients out of 389 patients in the during a mean follow-up of 55.5 +/- 12.7 months. The mean HCM Risk-SCD score of surviving patients was significantly lower than that of non-survivors (1.8% vs. 3.0%, p < .001). The HCM Risk-SCD score was above 6% in nine (2.6%) survivors and nine (19.1%) non-survivors (p < .001). The ROC curve based on the HCM Risk-SCD score had 61% sensitivity and 61% specificity for risk threshold of for 2.0%, 38% sensitivity and 99% specificity a threshold of >= 4%, 17% sensitivity, and 99% specificity for a threshold of >= 6%.Conclusion: A new risk algorithm with higher sensitivity is needed, although the HCM risk-SCD model is still quite useful in identifying patients at a high risk for SCD.